Clinical features, treatment, and outcome of pembrolizumab induced cholangitis

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

John B.A.G. Haanen, Michel Obéid, Lavinia Spain et al. · Annals of Oncology · 2022 · 1.2K citations · Full text

Pharmacy, Oncology, Toxicology +12

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

Albert Parés, Llorenç Caballería, Juan Rodés · Gastroenterology · 2006 · 758 citations · Full text

Medicine, Pathobiology, Hepatology +10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

Julie R. Brahmer, Christina Lacchetti, John A. Thompson · Journal of Oncology Practice · 2018 · 373 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacotherapy +10